ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib

References

• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–124.10.1056/NEJMoa065044
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–3590.10.1200/JCO.2008.20.1293
   PubMed Web of Science ®Google Scholar
• Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer. 2008;99(3):448–454.10.1038/sj.bjc.6604497
   PubMed Web of Science ®Google Scholar
• Garfield DH, Wolter P, Schoffski P, et al. Documentation of thyroid function in clinical studies with sunitinib: why does it matter? J Clin Oncol. 2008;26(31):5131–5132; author reply 2-3.10.1200/JCO.2008.18.8680
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–731.10.1056/NEJMoa1303989
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–1939.10.1016/S0140-6736(11)61613-9
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–927.10.1016/S1470-2045(16)30107-3
   PubMed Web of Science ®Google Scholar
• Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99(1):81–83.10.1093/jnci/djk008
   PubMedGoogle Scholar
• Rogiers A, Wolter P, Op de Beeck K, et al. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid. 2010;20(3):317–322.10.1089/thy.2009.0125
   PubMed Web of Science ®Google Scholar
• Ahmadieh H, Salti I. Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment. Biomed Res Int. 2013;2013:725410.
   PubMed Web of Science ®Google Scholar
• Brozik A, Hegedus C, Erdei Z, et al. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin Drug Metab Toxicol. 2011;7(5):623–642.10.1517/17425255.2011.562892
   PubMed Web of Science ®Google Scholar
• Haouala A, Widmer N, Duchosal MA, et al. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011;117(8):e75–e87.10.1182/blood-2010-07-294330
   PubMed Web of Science ®Google Scholar
• Shukla S, Robey RW, Bates SE, et al. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009;37(2):359–365.10.1124/dmd.108.024612
   PubMed Web of Science ®Google Scholar
• Hu S, Chen Z, Franke R, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009;15(19):6062–6069.10.1158/1078-0432.CCR-09-0048
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Karadimou A, Lambrechts D, et al. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer. 2013;108(4):887–900.10.1038/bjc.2012.548
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Lambrechts D, Van Brussel T, et al. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta Oncol. 2014:1–10.
   Web of Science ®Google Scholar
• Garcia-Donas J, Esteban E, Leandro-Garcia LJ, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011;12(12):1143–1150.10.1016/S1470-2045(11)70266-2
   PubMed Web of Science ®Google Scholar
• Mizuno T, Fukudo M, Fukuda T, et al. The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma. Ther Drug Monit. 2014;36(3):310–316.10.1097/FTD.0000000000000025
   PubMed Web of Science ®Google Scholar
• Narjoz C, Cessot A, Thomas-Schoemann A, et al. Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. Invest New Drugs. 2015;33(1):257–268.10.1007/s10637-014-0178-2
   PubMed Web of Science ®Google Scholar
• Low SK, Fukunaga K, Takahashi A, et al. Association study of a functional variant on ABCG2 gene with sunitinib-induced severe adverse drug reaction. PLoS One. 2016;11(2):e0148177.10.1371/journal.pone.0148177
   PubMed Web of Science ®Google Scholar
• Kim HR, Park HS, Kwon WS, et al. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer Chemother Pharmacol. 2013;72(4):825–835.10.1007/s00280-013-2258-y
   PubMed Web of Science ®Google Scholar
• Diekstra MH, Swen JJ, Boven E, et al. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur Urol. 2015;68:621–629.
   PubMed Web of Science ®Google Scholar
• Diekstra MH, Klumpen HJ, Lolkema MP, et al. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clin Pharmacol Therap. 2014;96(1):81–89.10.1038/clpt.2014.47
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Karadimou A, Lambrechts D, et al. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis. Acta Oncol. 2014;53(1):103–112.10.3109/0284186X.2013.770600
   PubMed Web of Science ®Google Scholar
• Eechoute K, van der Veldt AA, Oosting S, et al. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther. 2012;92(4):503–510.
   PubMed Web of Science ®Google Scholar
• Khan MS, Pandith AA, Iqbal M, et al. Possible impact of RET polymorphism and its haplotypic association modulates the susceptibility to thyroid cancer. J Cell Biochem. 2015;116(8):1712–1718.10.1002/jcb.v116.8
   PubMed Web of Science ®Google Scholar
• Reumers J, De Rijk P, Zhao H, et al. Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. Nat Biotechnol. 2012;30(1):61–68.10.1038/nbt.2053
   Web of Science ®Google Scholar
• Chu YH, Li H, Tan HS, et al. Association of ABCB1 and FLT3 polymorphisms with toxicities and survival in Asian patients receiving sunitinib for renal cell carcinoma. PLoS One. 2015;10(8):e0134102.10.1371/journal.pone.0134102
   PubMed Web of Science ®Google Scholar
• Mizuno T, Fukudo M, Terada T, et al. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics. Drug Metab Pharmacokinet. 2012;27(6):631–639.10.2133/dmpk.DMPK-12-RG-026
   PubMed Web of Science ®Google Scholar
• Mizuno T, Terada T, Kamba T, et al. ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Ann Oncol. 2010;21(6):1382–1383.10.1093/annonc/mdq150
   PubMed Web of Science ®Google Scholar
• van der Veldt AA, Eechoute K, Gelderblom H, et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res. 2011;17(3):620–629.10.1158/1078-0432.CCR-10-1828
   PubMed Web of Science ®Google Scholar
• Teo YL, Wee HL, Chue XP, et al. Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients. Pharmacogenomics J. 2016;16(1):47–53.10.1038/tpj.2015.13
   PubMed Web of Science ®Google Scholar
• Numakura K, Tsuchiya N, Kagaya H, et al. Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib. Anticancer Drugs. 2017;28(1):97–103.10.1097/CAD.0000000000000425
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Zucman-Rossi J. Kidney cancer: single nucleotide polymorphisms in mRCC-is their time up? Nat Rev Urol. 2015;12(8):424–426.10.1038/nrurol.2015.149
   PubMed Web of Science ®Google Scholar